Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:OLMA News 10 December 2025 - 29 January 2026

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals (OLMA) stock jumps 6% in a weak market — what to watch next

Olema Pharmaceuticals shares rose 5.8% to $25.99 Thursday afternoon, adding about $127 million in market value as broader indexes fell. Trading volume reached 926,000 shares. No new company news emerged, but traders are watching for Olema’s March update and progress on its late-stage palazestrant trial. The company reported over $500 million in cash and equivalents as of Dec. 31, 2025.
29 January 2026
·····
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

New York, Jan 11, 2026, 08:51 (EST) — Market closed. Olema Pharmaceuticals Inc shares closed up 9.8% on Friday at $28.08, with about 2.5 million shares changing hands, as investors headed into a catalyst-heavy week for the cancer drug developer. (The Wall Street Journal) U.S. markets reopen on Monday, and Olema is the kind of stock that can gap on a single slide deck. Conference remarks and fresh sell-side research tend to matter more than broad market tape for early-stage biotechs, at least for a day or two. Olema said CEO Sean P. Bohen will present at the J.P. Morgan
11 January 2026
·····
Olema Pharmaceuticals (OLMA) Stock: Weekend Read Ahead on the Pullback, Insider Sales, and Wall Street Targets Before Monday’s Open

Olema Pharmaceuticals (OLMA) Stock: Weekend Read Ahead on the Pullback, Insider Sales, and Wall Street Targets Before Monday’s Open

NEW YORK, Dec. 28, 2025, 6:44 a.m. ET — Market closed Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) heads into the final trading days of 2025 with investors trying to separate two very different realities: an explosive year-to-date run that put the breast-cancer biotech firmly on the growth-stock map—and a sharp late-December pullback that has reset near-term expectations. With U.S. markets closed for the weekend and set to reopen Monday, December 29, traders will be watching whether OLMA can stabilize after Friday’s decline and whether fresh headlines (or filings) emerge that could shift sentiment in either direction. Where OLMA stands heading into
28 December 2025
·····
Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

Olema Pharmaceuticals (OLMA) Stock Update: Weekend Snapshot, Insider Sales, Analyst Targets, and Key Catalysts Ahead of Monday

NEW YORK, Dec. 27, 2025, 8:26 PM ET — Market closed Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is heading into the weekend with investors weighing a sharp Friday pullback against a still-staggering multi-month run, a cluster of insider-trading filings, and a set of analyst price targets that continue to imply significant upside—if Olema’s late-stage breast cancer program delivers on its timeline. With U.S. equity markets closed Saturday and Sunday, the next meaningful price discovery for OLMA will come when regular trading resumes Monday, Dec. 29, at 9:30 a.m. ET. New York Stock Exchange OLMA stock price today: where Olema closed, and
28 December 2025
·····
Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals (NASDAQ: OLMA) Stock: Latest News, Analyst Forecasts, and What’s Driving the Volatility on December 19, 2025

Olema Pharmaceuticals, Inc. trades under the ticker OLMA (not “OLEM”) on Nasdaq. GlobeNewswire+1 On Friday, December 19, 2025, the stock was sharply lower intraday—$28.89, down $1.92 (-6.23%) at the latest published trade time in the market data feed, after opening $31.22 and swinging between $31.95 and $28.89. That kind of whiplash has become the defining feature of OLMA lately: it’s a clinical-stage oncology name where headline risk (trial readouts—yours or your rivals’) and financing mechanics (offerings, cash runway narratives) can move the stock fast. Below is a detailed roundup of the most relevant news, forecasts, and analysis available as of
19 December 2025
·····
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Published: December 10, 2025 Olema Pharmaceuticals Stock Rallies to Fresh Highs Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), which now brands itself as Olema Oncology, is having another breakout session on December 10, 2025. During Wednesday’s trading, OLMA: Over the past 12 months, OLMA’s share price has climbed from below $3 to nearly $30, according to Danelfin and CoinCodex ranges, reflecting a more than tenfold move at the extremes. Danelfin AI+1 Today’s spike is not a random move. It’s being driven by a cluster of catalysts that all hit investors’ screens at once: positive read‑through from a Roche breast cancer drug trial,
10 December 2025
···

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop